Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hemophilia a: Low-Dose emicizumab may protect joints better

NCT ID NCT07439055

Disease control Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether switching to low-dose emicizumab can improve joint health and reduce bleeding in people with hemophilia A who still have joint problems despite standard factor VIII therapy. Eighteen patients aged 8-28 from Thailand were enrolled. Those with worse joint scores were switched to low-dose emicizumab, and their bleeding rates, joint health, and quality of life were tracked for 8 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
emicizumab
What this could lead to
If successful, low-dose emicizumab could offer better bleeding control and joint health for hemophilia A patients who don't respond well to standard factor VIII therapy.
What could go wrong
This is a small, early-phase study with only 18 participants, so results may not apply to everyone. The low dose may not work as well as higher doses, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

18 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 30 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * hemophilia A patients aged 3-30 years who received treatment with PK-guided EHL Factor VIII for more than 8 months Exclusion Criteria: * hemophilia A patients with presence of factor VIII inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia A patient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemarthrosis hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia A patient

Contacts and locations

Locations

  • Chulalongkorn University

    Bangkok, 10330, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.